** Analysts at Morningstar maintain fair value estimates on Australian health companies, anticipating a change in U.S. President Donald Trump's position on pharmaceutical tariffs
** Trump said on Tuesday he plans to announce tariffs on imported pharmaceuticals to the U.S. which could reach 200%
** Investment research firm sees CSL CSL.AX being impacted by the tariffs as it processes some U.S. products in Australia, but doesn't expect earnings to take a material hit
** "Tariffs this high are unlikely to persist and CSL can adapt by onshoring manufacturing" - Morningstar
** Also anticipates Ansell ANN.AX, Polynovo PNV.AX, Nanosonics NAN.AX, and Fisher & Paykel FPH.NZ to be impacted, if tariffs come into effect
** Says Telix TLX.AX is enviably exempt from all potential tariffs on pharmaceuticals though shares remain overvalued
Morningstar Fair Value Estimates -
Stock | Fair Value Estimates |
CSL Ltd | A$325 |
Fisher & Paykel Healthcare | A$25 |
Ansell | A$36.50 |
A$19.50 | |
Nanosonics | A$4.30 |
Polynovo | A$1.15 |
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((JasmeenAraIslam.Shaikh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.